### **H A b e r t a**

Annual Report 2018-2019

# Aberta Partners

Alberta College of Pharmacy **Alberta Veterinary Medical Association** Alberta Dental Association and College Alberta Health **Alberta Health Services Alberta Medical Association Alberta Pharmacists' Association College and Association of Registered Nurses of Alberta College of Physicians & Surgeons of Alberta College of Podiatric Physicians of Alberta** Yukon Medical Council

# **TPP Alberta: About the Program**

The Triplicate Program was established in 1986 to monitor the use of certain medications prone to misuse and abuse for non-medical purposes.

### The TPP mandate is to:

- Monitor prescribing, dispensing and utilization practices regarding targeted medications;
- Improve patient care by providing relevant information and feedback on targeted drugs to prescribers and pharmacists;
- Provide timely and relevant information on targeted medications to consumers, regulatory bodies and stakeholders;
- Work with stakeholders to enable system-level change that ensures appropriate use of targeted medications;
- Ensure efficient and effective functioning of the TPP program.

# **TPP Alberta: 2018-2019 Highlights**

	P	T I IS		after 3 days			
ATRA	10	Tracked Prescription. Take to a pharmac PLEASE PRINT CLEARLY					
Alber	la		PLEASE	PRINT CLEARLY			
lealth care number							
Patient full name (Fi		DD MMM YYYY					
	Iromata			Date of Birth			
Patient address	Female			DD MMM YYYY			
the Anum			Browine				
.ity/town			Provino				
		h per form   Part	fills all	owed if interval specified*			
Juantity Numeric	Quanti	ty Alpha					
ndication for therap	y:	ADHD		leadache/Migraine			
Post-operative pair		Neuropathic pa	in 🗆 🤇	Opioid Agonist Therapy (OAT/OD1			
		Cancer/Palliati	ve				
	letal pain	Other (specify)					
	letal pain	Other (specify)					
TPP Tracking #:				Prescriber's Signature			
IPP Tracking #:				Date Dispensed			
TPP Tracking #: PHARMACY USE ON tx #		ID #:		Date Dispensed			
TPP Tracking #: PHARMACY USE ON tx # DIN	IIY:	ID #:		Date Dispensed			
TPP Tracking #: PHARMACY USE ON tx # DIN	ILY: teg. #	ID #:		Date Dispensed			

#### **New Two-Part Form**

After more than 30 years of using a three-part form to monitor drugs prone to misuse, TPP Alberta has moved to a two-part form to improve processes and save significant operational costs. Security of the form and submission requirements remain unchanged.

#### **Program Evolution**

Received Antibiotic data and formed a working group to inform data analytics.

### Collaboration

Started work with CARNA to develop a Nurse Practitioner MD Snapshot-Prescribing report. Collaborated with the Alberta Veterinary Medical Association (ABVMA) on antimicrobial stewardship initiatives.

# **TPP Alberta: 2018-2019 Highlights**



#### **TPP Medication List**

Continued to add, remove and/or change the status of Type 1 & 2 medications.

### **Data Quality**

Made enhancements to support TPP Alberta data quality capture.

#### **Data Utilization**

Contributed to efforts to help address the opioid crisis in Alberta.

### **TPP Alberta: Resources**

TPP Alberta Website TPP Alberta Medication List TPP Alberta Guide 2017 TPP Alberta Atlas



# **TPP Alberta: Data Utilization**



MD Snapshot: Prescribing Report




High-Risk Alert Letters




Mentorship & Education

Personalized reports based on TPP data sent to over 8,000 physicians prescribing opioids or benzodiazepines focusing on evidence-informed thresholds. Over 200 alert letters were sent to prescribers based on thresholds related to high OME, seeing multiple providers and multiple pharmacies in a three-month period. Daily Oral Morphine Equivalent (DOME) Program identified prescribers who had patients with very high OME values and paired them with an educational mentor.

# **TPP Alberta: OME Rates/1,000**




# **TPP Alberta: DDD Rates/1,000**



# **TPP Alberta: Member Prescribing**

#### **Opioid Prescribers 2018**

#### **Opioid Prescriptions 2018**



# **TPP Alberta: Member Prescribing**

#### **Benzo Prescribers 2018 Benzo Prescriptions 2018** Nurse Practitioners Pharmacists 0.7% 2.2% Dentists\* 0.6% Pharmacists 21.2% Veterinarians 0.2% Nurse Practicioners 2.5% Veterinarians 3.4% Dentists\* 0.6% Physicians 72.2% Physicians 96.3%

\*Most dental prescriptions are attributed to a pseudo identification number

# **2017 TPP Atlas: Analysis**


Figure 5. Age and Sex Standardized, Total OME per Day per 1,000 Population, by Pharmacy Local Aggregated Geographies, 2017

#### Table 1. Utilization of Prescription Opioids in Alberta, 2013-2017 Patients Patients ≥90 OME per Year Prescriptions Patients Prescribers Pharmacies Population Day per 1000 per 1000 OME per Day per **1000** Population Population Population 1,709,194 547,929 12,027 1,287 4,007,042 1,530 136.7 3.4 2013 2014 1,746,216 562,640 12,625 1,361 4,121,532 1,544 136.5 3.5 13,310 2015 1,753,275 563,549 1,367 4,196,192 1,514 134.3 3.5 14,167 1,413 135.9 3.5 2016 1,814,818 577,890 4,252,720 1,480 2017 1,702,052 547,819 14,577 1,374 4,285,997 1,277 127.8 3.0 5 year

#### Table 11. Utilization of Prescription Benzodiazepines in Alberta, 2013-2017

trend

Year	Prescriptions	Patients	Prescribers	Pharmacies	Population	DDDs per 1000 Population	Patients per 1000 Population	Elderly Patients per 1000 Elderly Population	Patients ≥ 2 DDDs per 1000 Population
2013	1,102,842	341,327	10,784	1,064	4,007,042	41.6	85.2	218.3	3.7
2014	1,178,213	358,752	11,369	1,332	4,121,532	42.3	87.0	218.2	3.8
2015	1,220,798	373,696	12,033	1,344	4,196,192	41.6	89.1	217.0	3.6
2016	1,284,730	386,901	12,739	1,414	4,252,720	41.1	91.0	214.7	3.5
2017	1,204,326	369,831	13,148	1,377	4,285,997	36.6	86.3	202.1	2.9
5 year trend									



# 2017 TPP Atlas: Trends

#### Table 7. Opioid Patients and Associated Prescribers by Dose, 2013-2017

atients							1			
Patient Dose*	20	13	2014		2015		2016		2017	
Fatient Dose	Patients	Percent								
Total Patients	547,929		562,640		563,549		577,890		547,819	
a 50 OME/day	22,070	4.0	23,311	4.1	24,093	4.3	24,695	4.3	22,325	4.0
a 90 OME/day	13,674	2.5	14,365	2.6	14,496	2.6	14,681	2.5	12,962	2.4
≥ 100 OME/day	12,492	2.3	13,108	2.3	13,204	2.3	13,310	2.3	11,668	2.1
≥ 200 OME/day	6,459	1.2	6,663	1.2	6,624	1.2	6,500	1.1	5,450	1.0
a 400 OME/day	2,592	0.5	2,621	0.5	2,527	0.5	2,382	0.4	1,898	0.4
≥ 600 OME/day	1,276	0.2	1,296	0.2	1,227	0.2	1,144	0.2	863	0.2
≥ 800 OME/day	749	0.1	759	0.1	681	0.1	602	0.1	448	0.1
a 1,000 OME/day	470	0.1	499	0.1	430	0.1	373	0.1	277	0.1
≥ 2,000 OME/day	85	0.0	75	0.0	67	0.0	48	0.0	40	0.0



Prescribers										
Patient Dose*	201 Prescribers	13 Percent	20 Prescribers	14 Percent	201 Prescribers	5 Percent	201 Prescribers	6 Percent	201 Prescribers	17 Percent
Total Prescribers	12,027		12,625		13,310		14,167		14,577	
a 50 OME/day	7,237	60.2	7,401	58.6	7,581	57.0	7,914	55.9	7,538	51.7
≥ 90 OME/day	6,195	51.5	6,210	49.2	6,218	46.7	6,498	45.9	5,977	41.0
a 100 OME/day	5,968	49.6	5,944	47.1	5,978	44.9	6,216	43.9	5,672	38.9
a 200 OME/day	4,355	36.2	4,344	34.4	4,256	32.0	4,328	30.5	3,683	25.3
≥ 400 OME/day	2,494	20.7	2,439	19.3	2,343	17.6	2,257	15.9	1,743	12.0
a 600 OME/day	1,441	12.0	1,474	11.7	1,388	10.4	1,323	9.3	917	6.3
a 800 OME/day	922	7.7	939	7.4	812	6.1	735	5.2	515	3.5
≥ 1,000 OME/day	582	4.8	663	5.3	513	3.9	485	3.4	317	2.2
a 2,000 OME/day	110	0.9	98	0.8	74	0.6	53	0.4	52	0.4

\* can include prescriptions from multiple prescribers

and have

#### Table 18. Benzodiazepine Patients and Associated Prescribers by Number of Ingredients, 2013-2017

Patients												
Number of Ingredients		013 Percent	20 Patients	14 Percent	201 Patients	15 Percent	201 Patients	l6 Percent	20 Patients	17 Percent	2017	5 Year Trend
Total Patients	341,327		358,752		373,696		386,901		369,831			
2+	70,382	20.6	75,098	20.9	77,796	20.8	80,267	20.7	70,268	19.0		
3+	13,568	4.0	14,442	4.0	14,541	3.9	15,051	3.9	11,437	3.1		
4+	2,696	0.8	2,919	0.8	2,774	0.7	2,854	0.7	1,783	0.5		
5+	544	0.2	594	0.2	550	0.1	552	0.1	274	0.1		
6+	109	0.0	115	0.0	116	0.0	119	0.0	50	0.0		

#### Prescribers

Number of	201	-	201								2017				2017	5 Year
Ingredients	Prescribers	Percent		Trend												
Total Prescribers	10,784		11,369		12,033		12,739		13,148							
2+	8,285	76.8	8,883	78.1	9,358	77.8	9,909	77.8	9,975	75.9		$\sim$				
3+	5,521	51.2	5,955	52.4	6,181	51.4	6,584	51.7	6,338	48.2		$\sim$				
4+	3,003	27.8	3,208	28.2	3,231	26.9	3,440	27.0	2,943	22.4						
5+	1,292	12.0	1,462	12.9	1,333	11.1	1,419	11.1	879	6.7	1					
6+	448	4.2	501	4.4	497	4.1	478	3.8	206	1.6						



# **TPP Alberta Grant Report: Financial Summary**

				GAMS Grant ID	(	Grant-004961
				UNAUDITED FINAN		G FOR GRANT R AGREEMEN YEAR 2 of
Grant Recipient: Description of Grant:	College of Physicia Triplicate Prescrip		f Alberta			
Term of Agreement: Financial Reporting for the Period:	1-Apr-17 1-Apr-18	to to	31-Mar-20 31-Mar-19	Da	ate: _	24-May-
	Cu	rrent Fiscal Period: Year-To-Date			Term of Agreement reement-To-Date	
	Budget	Actuals	Variance	Budget	Actuals	Variano
	12 months	12 months		24 months	24 months	
Revenue						
Contribution from Alberta Health &						
Wellness (Surplus)	-		•	23,793.56	23,793.56	-
Contribution from Alberta Health &						
Wellness	660,000.00	660,000.00	1	1,296,206.44	1,196,206.44	( 100,000.0
Government Grant - Investment		( ( ( 0 0 0 )			000.04	
Income		(418.36)	(418.36)		669.84	669.8
Grant - Other Sources	151,000.00	135,400.00	(15,600.00)	278,000.00	264,025.00	(13,975.0
CPSA Contribution Total Revenue	158,300.00	156,759.00 951,740.64	(1,541.00) (17,559.36)	309,300.00 1,907,300.00	308,709.00 1,793,403.84	( 591.0
Total Revenue	909,300.00	551,740.04	(17,558.50)	1,307,300.00	1,755,405.04	(115,050.1
Expense						
General Program Expenditures						
Consulting	191,200.00	221,469.72	30,269.72	357,600.00	384,679.11	27,079.1
Legal	3,000.00		(3,000.00)	6,000.00		(6,000.0
Occupancy Costs	53,700.00	40,899.00	(12,801.00)	104,300.00	90,024.01	(14,275.9
Operating Costs	62,500.00	61,149.98	(1,350.02)	125,700.00	121,799.99	(3,900.0
Printing, Supplies & Courier	23,200.00	33,217.42	10,017.42	44,900.00	50,850.08	5,950.0
Special printing	340,000.00	306,245.43	(33,754.57)	665,500.00	608,515.30	(56,984.7
Travel, Meals & Accommodation	······	45.60	45.60	S#1	45.60	45.6
Sub-total	673,600.00	663,027.15	(10,572.85)	1,304,000.00	1,255,914.09	( 48,085.9

# **TPP Alberta Grant Report: Financial Summary Cont'd**

Name	Position / Phone #		ate		ignature	
Finance Approval: Karen Mazurek	Deputy Registrar (780) 969-4957	٢	ay 30,20	19	K	<u> </u>
Name	Phone #	N	ame			Phone #
Tracy Simons	780-969-4983		d Jess			(780) 969-4946
inance Contact:		P	rogram Contact:			
Retention of Unexpended Funding Form (FINAL YEAR ONLY)	Less: Approved Re Closing Balance:	<deficit></deficit>		Funding (FINAL YE	AR ONLY)	10,341.70
Attached Request(s) for	Add (Subract) Curre	ent Surplus/ (Deficit	t): Y	ear 2		16,929.40
Inexpended Funding	Opening Balance:			ear 1		( 6,587.70
	7	10,020,10				
Surplus < Deficit >		16,929.40	16,929,40		10,341,70	10.341.70
Total Expenses	969,300.00	934,811.24	( 34,488.76 )	1,907,300.00	1,783,062.14	( 124,237.86
Sub-total	1. S.	104.68	104.68	-	195.81	( 195.81
Committee Expenses Travel, Meals & Accommodation, Sundry		104.68	104.68		195.81	195.81
Sub-total	295,700.00	271,679.41	(24,020.59)	603,300.00	526,952.24	(76,347.76
Professional Development	3,700.00	1,269.08	(2,430.92)	6,900.00	2,009.32	( 4,890.68
Staffing Costs Salaries & Benefits	292,000.00	270,410.33	(21,589.67)	596,400.00	524,942.92	(71,457.08